$385+ Million Cholangiocarcinoma (CCA) Market Insights, 2019: Epidemiology & Market Forecast to 2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 15, 2019--The “Cholangiocarcinoma (CCA)- Market Insights, Epidemiology and Market Forecast to 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cholangiocarcinoma (CCA) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cholangiocarcinoma (CCA) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography CoveredThe United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan
Study Period: 2017-2028
According to this research, the incident population of Cholangiocarcinoma (CCA) was estimated to be 18,729 [7MM] in 2018. United States accounts for the highest CCA cases (6,971 in 2018), followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest incident patient population of Cholangiocarcinoma, followed by Italy.
Cholangiocarcinoma (CCA) Management
The current market size for early stage Cholangiocarcinoma (CCA) majorly includes surgery with adjuvant chemotherapy and chemoradiation therapy. For the advanced and metastatic stage, systemic chemotherapy is the only option. There is no established second-line systemic therapy following progression after first-line treatment although chemotherapeutic agents either in monotherapy or in combination are used.
The primary unmet need of Cholangiocarcinoma (CCA) treatment market is the dearth of approved targeted therapies. To meet the increasing demand for the treatment of Cholangiocarcinoma (CCA), companies have shifted their focus towards the development of targeted therapies. Due to the novel and target-specific mechanism of action for Cholangiocarcinoma (CCA), the overall market size of off-label therapies will experience modest rise in the US to till 2020.
According to this research, the global market of Cholangiocarcinoma (CCA) was estimated to be USD 385.07 million in 2018. The United States accounts for the largest market size of Cholangiocarcinoma, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Currently, includes surgery with adjuvant chemotherapy and chemoradiation therapy. For the advanced and metastatic stage, systemic chemotherapy is the only option. There is no established second-line systemic therapy following progression after first-line treatment although chemotherapeutic agents either in monotherapy or in combination are used.
To meet the increasing demand for the treatment of Cholangiocarcinoma (CCA), companies have shifted their focus towards the development of targeted therapies. Expected launch of potential targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma, may increase the market size in the coming years, assisted by an increase in the incident population of Cholangiocarcinoma (CCA) & awareness of the disease.
The dynamics of Cholangiocarcinoma market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028.
Key players are working robustly on new therapies with novel mechanism of action, including Ivosidenib (Agios Pharmaceuticals), Pemigatinib (Incyte Corporation), Infigratinib (QED Therapeutics), Melphalan Hydrochloride (Delcath Systems), Regorafenib (Bayer), Larotrectinib (Loxo Oncology), Entrectinib (Hoffmann-La Roche), Derazantinib (Basilea Pharmaceutica) and Erdafitinib(Janssen Research & Development).
Companies MentionedAgios Pharmaceuticals Incyte Corporation QED Therapeutics Delcath Systems Basilea Pharmaceutica Bayer Loxo Oncology Janssen Pharmaceutical Roche
Report InsightsPatient Population Therapeutic Approaches Pipeline Analysis Market Size and Trends Market Opportunities Impact of upcoming Therapies
Report Key Strengths10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition
Report AssessmentCurrent Treatment Practices Unmet Needs Detailed Pipeline Product Profiles Market Attractiveness Market Drivers and Barriers
Key BenefitsThis report will help to develop Business Strategies by understanding the trends shaping and driving the Cholangiocarcinoma (CCA) market. Organize sales and marketing efforts by identifying the best opportunities for Cholangiocarcinoma (CCA) market. To understand the future market competition in the Cholangiocarcinoma (CCA) market.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/f9cmnd/385_million?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190215005184/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Liver Cancer Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/15/2019 06:19 AM/DISC: 02/15/2019 06:19 AM